Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2020 Jul 17.

Published in final edited form as: J Allergy Clin Immunol. 2017 Apr 4;140(3):875–879.e1. doi: 10.1016/j.jaci.2017.03.013

FIG 1. — Ibrutinib inhibits basophil and mast cell activation in 2 subjects prescribed ibrutinib for CLL treatment. A, Demographic characteristics, BTK inhibitor clinical indication, ibrutinib dose, and IgE levels are listed for each subject. B, Skin test responses to cat allergen (subject 1) and ragweed (subject 2) before and during ibrutinib treatment (420 mg daily) in 2 patients being treated for CLL. C, Basophil activation responses to anti-IgE (72% and 89% positive, respectively, before starting ibrutinib) or fMLP (12% and 16% positive, respectively, before starting ibrutinib) are shown for these same 2 subjects.

FIG 1. — Ibrutinib inhibits basophil and mast cell activation in 2 subjects prescribed ibrutinib for CLL treatment. A, Demographic characteristics, BTK inhibitor clinical indication, ibrutinib dose, and IgE levels are listed for each subject. B, Skin test responses to cat allergen (subject 1) and ragweed (subject 2) before and during ibrutinib treatment (420 mg daily) in 2 patients being treated for CLL. C, Basophil activation responses to anti-IgE (72% and 89% positive, respectively, before starting ibrutinib) or fMLP (12% and 16% positive, respectively, before starting ibrutinib) are shown for these same 2 subjects.